Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can adding shockwaves to platelet therapy boost erectile function?

NCT ID NCT07783347

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether combining platelet-rich plasma (PRP) injections with low-intensity shockwave therapy works better than PRP alone for men with erectile dysfunction. Eighty men aged 30-65 with mild to moderate erectile dysfunction will be randomly assigned to one of two groups. One group receives PRP injections alone, while the other receives PRP plus shockwave therapy. The study measures changes in erectile function, erection hardness, penile blood flow, and patient satisfaction to see if the combination offers greater improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP) injections, alone or combined with low-intensity extracorporeal shock wave therapy (Li-ESWT)
What this could lead to
If adding shockwave therapy to PRP improves erectile function more than PRP alone, it could offer a more effective non-surgical treatment option for men with erectile dysfunction.
What could go wrong
This is a small, early-stage trial, and results may not apply to all men. PRP and shockwave therapies are still experimental for this condition, and their benefits and risks are not fully established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male participants aged 30-65 years. * Diagnosis of erectile dysfunction for at least 3 months. * Mild to moderate erectile dysfunction, defined by an International Index of Erectile Function-5 (IIEF-5) score of 8-21. * In a stable heterosexual relationship for at least 6 months. * Sexually active, with at least one sexual attempt per week. Exclusion Criteria: * Severe erectile dysfunction, defined as IIEF-5 score \<8. * Primary psychogenic erectile dysfunction based on clinical history with or without psychosexual assessment. * Anatomical penile abnormalities, including Peyronie's disease. * History of radical pelvic surgery or pelvic radiotherapy. * Uncontrolled diabetes mellitus, defined as HbA1c \>9%. * Uncontrolled hypertension, defined as blood pressure \>160/100 mmHg. * Recent myocardial infarction or stroke within the previous 6 months. * Unstable angina. * New York Heart Association class III-IV heart failure. * Severe hepatic impairment. * Severe renal impairment. * Hypogonadism, defined as total testosterone \<300 ng/dL. * Hyperprolactinemia. * Untreated thyroid disease. * Current use of nitrates or nitric oxide donors. * Current use of alpha-blockers, unless the participant is on a stable low dose. * Current use of other phosphodiesterase type 5 inhibitors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erectile dysfunction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erectile dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.